uniQure N.V. (QURE) Investors: Deadline for Securities on April 13, 2026

Investors who purchased shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, are facing a critical deadline to participate in a securities fraud class action lawsuit filed by Kessler Topaz Meltzer & Check, LLP. The lawsuit alleges that uniQure made material misstatements and omissions regarding its Huntington’s disease gene therapy drug during that period. Investors who wish to seek lead plaintiff status in the case have until April 13, 2026, to do so.

uniQure is a biotechnology company that specializes in developing gene therapies for rare diseases, such as Huntington’s disease. One of its key drug candidates is AMT-130, a novel gene therapy aimed at slowing the progression of Huntington’s disease. However, during the Class Period specified, uniQure allegedly provided misleading information about the Phase I/II clinical trials of AMT-130 and the timeline for submitting a Biologics License Application (BLA) to the FDA for approval to use the drug in treating HD patients.

The complaint asserts that uniQure, along with its executives, made false and misleading statements about the company’s operations and business throughout the Class Period. Specifically, they were accused of not fully disclosing that the design of the Pivotal Study, which included comparing its results to an external historical data set, was not entirely approved by the FDA. Additionally, the defendants allegedly understated the likelihood of delays in the BLA timeline, despite reportedly successful trial results.

The truth about uniQure’s situation emerged on November 3, 2025, when the company revealed that the FDA did not agree with the adequacy of the data from the Phase I/II studies of AMT-130 when compared to an external control. As a result, uniQure had to reconsider its BLA submission timeline. This news caused a significant drop in the price of uniQure shares, falling over 49% in a single day.

Investors who purchased uniQure shares during the Class Period and suffered financial losses have the option to take action. They can choose to become the lead plaintiff in the class action lawsuit by filing before the April 13, 2026 deadline. Contacting Kessler Topaz Meltzer & Check, LLP will provide a chance for a free evaluation of the case to understand the recovery options available.

Ultimately, uniQure investors have a crucial decision to make by the approaching deadline. They can either move to be the lead plaintiff in the securities fraud class action lawsuit or explore other legal options available to them. Time is of the essence for affected investors to ensure they are represented in the ongoing litigation accurately.